Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Learn what a good retirement plan percentage is to maximize your savings. Understand how much to contribute for a secure financial future.
20,067 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
TeraWulf stunned investors with a powerful April rally, rising about 50% as crypto momentum and cost discipline colli...
The AI race keeps evolving, and Alphabet sits at the center. A rumored Anthropic cloud deal hints at how hyperscale i...
A large fund snapped up 1.2 million Vir Biotechnology shares as the stock doubled this past year. Here’s how to read ...
Berkshire Hathaway kicked off the year with bold portfolio changes. In Q1, the company swapped key holdings and redir...
A large fund sold a substantial stake in Kennametal, igniting questions about the stock's trajectory. This article br...
As AI workloads push memory demand higher, micron stock could have substantial upside. Yet a high-capex Virginia expa...
Can the steady, branch-backed lender OneMain outpace the AI-powered growth of Upstart? This guide breaks down the str...
As 2026 unfolds, investors face a choice between two very different travel giants. One leans on software and hosts to...
An executive stock sale can signal many things. This article breaks down the numbers, the reporting rules, and practi...
Grab's CEO recently sold 400,000 Class A shares for about $1.6 million. This insider move raises the question: should...
DraftKings posted strong top-line growth yet issued cautious guidance, sending its stock lower. This analysis breaks ...